COVID-19: Are Monoclonal Antibodies What the CLL Community Has Been Waiting For?

Thursday, December 2, 2021

9:30 AM PT, 10:30 AM MT, 11:30 AM CT, 12:30 PM ET (Duration 75 minutes)


While vaccines may be the best solution to the COVID-19 pandemic for the majority, CLL patients need an additional solution as vaccine response is variable and often impaired. Learn about monoclonal antibodies (mAbs) directed against the virus that causes COVID-19, which may be our best answer from Dr. Shahzad Mustafa, an immunology expert, and CLL Society’s own Dr. Brian Koffman and Robyn Brumble, RN.



Patty Koffman 
Co-Founder and Communications Director, CLL Society 


Brian Koffman, MDCM (retired), MS Ed
Co-Founder, Executive Vice President, and Chief Medical Officer, CLL Society 


S. Shahzad Mustafa, MD
Lead Physician – Allergy, Immunology, & Rheumatology
Rochester Regional Health
Clinical Associate Professor of Medicine
University of Rochester School of Medicine and Dentistry


Robyn Brumble, MSN, RN
Director of Scientific Affairs,
CLL Society

This program was made possible by grant support from Adaptive Biotechnologies, Bristol Myers Squibb, Pharmacyclics, Janssen, and Regeneron.